PathNet Expands Urologic Pathology Offerings with In-House PTEN and FGFR3 Biomarker Testing
核心洞察
PathNet (搜索), a leading independent urologic oncology pathology laboratory, announced it will offer PTEN (搜索) and FGFR3 (搜索) biomarker staining in-house to guide treatment decisions for prostate and bladder cancer (搜索) patients.
The PTEN (搜索) biomarker detects PTEN protein loss in prostate cancer (搜索) tumors, a finding associated with tumor aggressiveness and used to inform clinical management.
The FGFR3 (搜索) biomarker identifies FGFR3 protein presence, a driver of alteration in papillary urothelial carcinoma (搜索), and helps differentiate low-grade from high-grade disease.
PathNet (搜索), one of the nation's foremost pathology laboratories and largest independent urologic oncology pathology networks, announced it will offer PTEN (搜索) and FGFR3 (搜索) biomarker stains in-house in its laboratory. These assays measure the expression levels of the PTEN and FGFR3 proteins in prostate and bladder cancer (搜索) patients to help guide treatment.
The expansion strengthens PathNet (搜索)'s already robust urologic pathology offerings by bringing two clinically relevant biomarkers directly into its laboratory workflow. Performed in-house, the PTEN (搜索) biomarker is used to determine PTEN protein loss in tumors of patients with prostate cancer (搜索), which is associated with tumor aggressiveness. The FGFR3 (搜索) biomarker is used to determine the presence of the FGFR3 protein, a driver of alteration in papillary urothelial carcinoma (搜索).
Clinical Utility of the New Biomarkers
The two assays serve distinct but complementary roles in urologic oncology. The PTEN (搜索) biomarker can be ordered conditionally based on clinician criteria or individually per case, providing flexibility in how clinicians deploy the test to assess tumor aggressiveness in prostate cancer (搜索) patients.
The FGFR3 (搜索) biomarker is a pathologist-ordered stain used to help differentiate between low-grade and high-grade papillary urothelial carcinoma (搜索). By identifying the presence of the FGFR3 protein, pathologists gain additional information to support more precise tumor classification in bladder cancer (搜索) cases.
Strategic Rationale
"Continually adding biomarker testing, such as PTEN (搜索) and FGFR3 (搜索), is integral to allowing the clinicians we serve to make treatment decisions backed with data from their patient's individual cancer progression," said Jason Camilletti, CEO of PathNet (搜索). "Bringing these biomarkers in-house allows us to better serve our clients and provide better patient care."
The move reflects PathNet (搜索)'s broader commitment to leveraging advanced technology to improve patient outcomes. As a digital pathology laboratory, PathNet employs digital solutions that extend beyond the pathologist and into clinic workflows, enabling faster tissue processing, improved turnaround times, and more detailed results that support personalized care and treatment for each patient.